Stevanato Group (STVN) Teams Up With Aptar Pharma, Is 21% Undervalued Too Optimistic?

Aptar Pharma’s new collaboration with Stevanato Group (STVN) focuses on generating system-level data for prefilled syringe setups used in sensitive biologics and injectable therapies. The partnership directly targets packaging choices and regulatory considerations for drug developers.

For investors tracking Stevanato Group, the collaboration comes after a softer period in the market, with the share price down 5.9% over the past 90 days and the 1-year total shareholder return declining 22.9%. This points to fading momentum despite ongoing operational initiatives.

Scan beyond Stevanato Group and see how other complex drug delivery specialists are pricing in similar packaging and biologics trends with the curated 19 high quality undiscovered gems.

Stevanato Group shares have already shed a chunk of optimism, yet the business still reports revenue of €1,225.227m and net income of €134.607m. Is most of the rerating now behind the stock, or still ahead?

Most Popular Narrative: 21% Undervalued

Stevanato Group’s most followed narrative places fair value at about $24.47, comfortably above the last close of $19.38. This frames today’s weakness against a more optimistic long term view built on mix and margin.

The growing prevalence of biologics and novel drug classes, including GLP‑1s, mAbs and biosimilars, continues to line up with Stevanato Group’s mix shift toward high value Nexa and Alba syringes and EZ‑fill formats. These products are now reported at 45% to 47% of revenue and support a higher margin revenue profile.

Rising pharmaceutical industry investment in U.S. manufacturing and supply chain localization is feeding into Stevanato Group’s build out of the Fishers facility as a North American hub, with management targeting a move from roughly 0% gross margin at Fishers toward more than 30% as utilization increases. This would influence group level gross margin and EBITDA margin.

See why 5 investors see Stevanato Group as 21% undervalued.

Result: Fair Value of $24.47 (UNDERVALUED)

Still, the Stevanato Group story depends heavily on higher margin sites like Fishers ramping up as planned and on GLP 1 related demand not cooling faster than expected.

Find out about the key risks to this Stevanato Group narrative.

Next Steps

Reading Stevanato Group’s recent swings and mixed signals on risks and rewards, you should now pressure test the data yourself and move fast to shape an independent view with 4 key rewards and 1 important warning sign.

Looking for more Stevanato Group sized opportunities?

If you stop with Stevanato Group, you miss the broader picture. Put a shortlist together now and keep fresh ideas ready before the next move.

• Target resilient balance sheets and steady fundamentals with a curated list of solid balance sheet and fundamentals (24 results) to anchor your portfolio around financially sound businesses.
• Hunt for pricing gaps where quality and valuation still line up by scanning the 33 high quality undervalued stocks before others catch on.
• Secure more predictable cash returns by filtering for income focused ideas using a focused 5 dividend fortresses that highlights higher yielding options.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com